Marburg I mutant af faktor VII aktiverende protease (FSAP) som risikofaktor for arteriel thrombose

Risk factor (RF1) for diagnosing genetic predisposition to atherosclerosis comprises a mutation in the blood coagulation factor VII-activating protein (FSAP). Independent claims are also included for the following: (1) risk factor (RF2) for atherosclerosis that is a reduced potential for activation...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WEIMER, THOMAS, DOERSAM, VOLKER, WILLEIT, JOHANN, KIECHL, STEFAN, FEUSSNER, ANNETTE, WIEDERMANN, CHRISTIAN JOSEF, STOEHR, HANS-ARNOLD, ROEMISCH, JUERGEN
Format:	Patent
Sprache:	dan
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Risk factor (RF1) for diagnosing genetic predisposition to atherosclerosis comprises a mutation in the blood coagulation factor VII-activating protein (FSAP). Independent claims are also included for the following: (1) risk factor (RF2) for atherosclerosis that is a reduced potential for activation of single-chain plasminogen activators (A), especially pro-urokinase; (2) recognizing a genetically dependent predisposition to develop atherosclerosis, or formation of thrombi, by detecting in a body fluid, especially plasma, reduced FSAP-antigen concentration or reduced FSAP activity; (3) test system for method (2); and (4) determining antibodies against FSAP and/or its mutant by incubating test sample with a solid phase to which FSAP and/or its mutant are bound, then washing and detecting bound antibodies.